Fundz

AnaCardio raises €62.5M in Series B funding at lower valuation, impacting investor KDventures' portfolio value.

PRIVATESep 30, 2026

Amount Raised

€62.5 Million

Round Type

Series B

StockholmSoftwareHealth Care

Description

AnaCardio completed a €62.5M Series B funding round, though at a lower valuation than previously anticipated. KDventures AB, an existing investor, chose not to participate in the round and will write down its stake accordingly. The write-down reflects a €30.0M (49.5%) negative adjustment to KDventures' carrying value of the investment, reducing it to approximately €30.6M. AnaCardio's ownership structure now shows KDventures at approximately 2.3% on a fully diluted basis.

Quick answer

AnaCardio raised €62.5 Million in a Series B round, dated September 30, 2026. AnaCardio is based in Stockholm, Stockholm County, Sweden.

How much did AnaCardio raise?
AnaCardio raised €62.5 Million in a Series B round on September 30, 2026.
What does AnaCardio do?
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
Where is AnaCardio based and how big is it?
AnaCardio is based in Stockholm, Stockholm County, Sweden. Fundz records about 27 employees.
Who are the decision-makers at AnaCardio?
Fundz holds 1 contact at AnaCardio, including the CEO. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Software and Health Care around the same time

Companies in the same sectors as AnaCardio that raised within 45 days of this round, from Fundz verified event records.

  • MyoWorks raised an undisclosed amount on November 10, 2026.
  • Apple raised an undisclosed amount (Debt Financing) on November 5, 2026.
  • Laza Medical raised $160M (Series B) on November 4, 2026.
  • TailorMed raised an undisclosed amount (Private Equity) on November 2, 2026.
  • ClarityCare raised $16M (Series A) on October 27, 2026.
  • Ambiki raised an undisclosed amount on October 23, 2026.

Who to call at AnaCardio, and when

A new round usually means AnaCardio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AnaCardio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AnaCardio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AnaCardio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AnaCardio

Location

Stockholm, Stockholm County, Sweden

About

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AnaCardio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsPatrik S., CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AnaCardio's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

AnaCardio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.